title: Targeting the molecular defect in BRCA-deficient tumors for cancer therapy.
abstract: Targeted therapies exploiting specific molecular defects in cancer cells promise to overcome roadblocks in the development of effective anticancer drugs. A recent report in the New England Journal of Medicine on the early clinical evaluation of Olaparib in cancers lacking the BRCA1 or BRCA2 genes exemplifies this promising new trend.
authors: The Medical Research Council Cancer Cell Unit, Hutchison/MRC Research Centre, Cambridge, UK. arv22@cam.ac.uk
authors: Ashok R
authors: AR
authors: Venkitaraman
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D019313:BRCA1 Protein / Q000235:genetics* / Q000502:physiology; D024682:BRCA2 Protein / Q000235:genetics* / Q000502:physiology; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics; D017321:Clinical Trials, Phase I as Topic; D015195:Drug Design; D005260:Female; D020022:Genetic Predisposition to Disease; D018095:Germ-Line Mutation; D006801:Humans; D010793:Phthalazines / Q000009:adverse effects / Q000627:therapeutic use*; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use*; D000067856:Poly(ADP-ribose) Polymerase Inhibitors
chemical_list: D000970:Antineoplastic Agents; D019313:BRCA1 Protein; D024682:BRCA2 Protein; D010793:Phthalazines; D010879:Piperazines; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; C531550:olaparib